

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

03 AUG 14 PM 12: 01

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Ropes & Gray			
2. Address <input type="checkbox"/> Check if different than previously reported 1301 K St. NW, Suite 800 East			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20005			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
Thomas M. Susman	(202) 626-3920	tsusman@ropesgray.com	3368
7. Client Name <input type="checkbox"/> Self Novartis Pharmaceuticals Corporation			6. House ID # 3072

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-Dec)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more ⇒ \$ 20,000.00
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000

\$10,000 or more ⇒ \$ _____
Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of

Method A. Reporting amounts using LDA definition

Method B. Reporting amounts under section 603 Internal Revenue Code

Method C. Reporting amounts under section 162 Internal Revenue Code

Signature _____

Printed Name and Title _____

LD-2 (REV. 6/98)

f

Registrant Name Ropes & Gray Client Name Novartis Pharmaceuticals Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the r engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code information as requested.** Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare reimbursement for oral anti-cancer therapies.
H.R. 1288; S. 1037


17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Sam Turner, Partner	
Elizabeth Goss, Partner	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/06/03

Printed Name and Title Thomas M. Susman, Partner

Form LD-2 (Rev. 6/98)

Page